Using the IDO1 inhibitor GDC-0919, we demonstrate that although a reduction is Kyn is observed, it is not complete (Fig. 1e), which may be attributed to parallel pathways a tumor may utilize to generate this metabolite independent of IDO1 or incomplete enzyme inhibition by this compound. Here, IDO1 is linked to neoplasm.